Cowen & Co. Keeps Their Buy Rating on Orchard Therapeutics (ORTX)

By Austin Angelo

Cowen & Co. analyst Yaron Werber maintained a Buy rating on Orchard Therapeutics (ORTXResearch Report) today and set a price target of $28.00. The company’s shares closed last Monday at $11.39.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 16.5% and a 68.4% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Springworks Therapeutics, and Rocket Pharmaceuticals.

Orchard Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $26.67.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.64 and a one-year low of $8.65. Currently, Orchard Therapeutics has an average volume of 210.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of gene therapies. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies.